学科主题 | 临床医学 |
HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome | |
Chen, Y.; Liu, K.; Xu, L.; Chen, H.; Liu, D.; Zhang, X.; Shi, H.; Han, W.; Wang, Y.; Zhao, T.; Wang, J.; Wang, J.; Huang, X. | |
关键词 | Myelodysplastic Syndrome Hematopoietic Sct Allogeneic Hla Haploidentical Mismatched |
刊名 | BONE MARROW TRANSPLANTATION
![]() |
2010-08-01 | |
DOI | 10.1038/bmt.2009.351 |
卷 | 45期:8页:1333-1339 |
收录类别 | SCI |
文章类型 | Article |
WOS标题词 | Science & Technology |
类目[WOS] | Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation |
资助者 | Key Projects in the National Science & ; Technology Pillar Program ; National Science Foundation for Distinguished Young Scholars of China ; Innovation team by the Ministry of Education ; Key Projects in the National Science & ; Technology Pillar Program ; National Science Foundation for Distinguished Young Scholars of China ; Innovation team by the Ministry of Education |
研究领域[WOS] | Biophysics ; Oncology ; Hematology ; Immunology ; Transplantation |
关键词[WOS] | BONE-MARROW-TRANSPLANTATION ; LEUKEMIA WORKING PARTY ; IDENTICAL SIBLINGS ; DONOR ; BLOOD ; CYCLOPHOSPHAMIDE ; CHEMOTHERAPY ; BUSULFAN ; RELAPSE ; GRAFTS |
英文摘要 | Allogeneic hematopoietic SCT (HSCT) is currently the only curative treatment for myelodysplastic syndrome (MDS). However, many patients cannot find an HLA-matched donor. We have developed a new protocol for HLA-mismatched (including haploidentical) HSCT using G-CSF-primed BM plus G-CSF-mobilized PBSCs without in vitro T-cell depletion. A total of 36 patients diagnosed with high-risk MDS (RAEB (refractory anemia with excess blasts) or RAEBt (RAEB in transformation)) underwent transplantation from HLA-mismatched family donors. All patients achieved sustained myeloid engraftment. The cumulative incidence of grades II-IV acute GVHD (aGVHD) was 60% and that of grades III and IV aGVHD was 15%. The 2-year cumulative incidence of chronic GVHD was 56%. After a median follow-up of 17 months, 4 patients had relapsed and died and 25 patients were still alive. The 2-year probability of leukemia-free survival (LFS) was 65%. Patients transplanted within 7 months of diagnosis had better LFS (89 vs 43%). Severe aGVHD decreased the LFS significantly by increasing non-relapse mortality (NRM). This study confirms that HLA-mismatched HSCT is a treatment option for MDS. Patients with high-risk MDS benefit from receiving HSCT early in the course of the disease. Bone Marrow Transplantation (2010) 45, 1333-1339; doi: 10.1038/bmt.2009.351; published online 11 January 2010 |
语种 | 英语 |
所属项目编号 | 2008BAI61B02 ; 30725038 ; IRT0702 |
资助者 | Key Projects in the National Science & ; Technology Pillar Program ; National Science Foundation for Distinguished Young Scholars of China ; Innovation team by the Ministry of Education ; Key Projects in the National Science & ; Technology Pillar Program ; National Science Foundation for Distinguished Young Scholars of China ; Innovation team by the Ministry of Education |
WOS记录号 | WOS:000280777400011 |
Citation statistics | |
文献类型 | 期刊论文 |
条目标识符 | http://ir.bjmu.edu.cn/handle/400002259/50111 |
Collection | 北京大学第二临床医学院_血液科 |
作者单位 | Peking Univ, Inst Hematol, Peoples Hosp, Beijing 100044, Peoples R China |
Recommended Citation GB/T 7714 | Chen, Y.,Liu, K.,Xu, L.,et al. HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome[J]. BONE MARROW TRANSPLANTATION,2010,45(8):1333-1339. |
APA | Chen, Y..,Liu, K..,Xu, L..,Chen, H..,Liu, D..,...&Huang, X..(2010).HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome.BONE MARROW TRANSPLANTATION,45(8),1333-1339. |
MLA | Chen, Y.,et al."HLA-mismatched hematopoietic SCT without in vitro T-cell depletion for myelodysplastic syndrome".BONE MARROW TRANSPLANTATION 45.8(2010):1333-1339. |
Files in This Item: | There are no files associated with this item. |
Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.
Edit Comment